|
|
How lupus T cells lose IL-2
Apr 3, 2005, 13:11, Reviewed by: Dr.
|
|
The researchers find that sera from lupus patients contains antibodies that bind to T cells and activate a complex cellular signaling cascade that ultimately results in decreased IL-2 production. This deficiency in IL-2 could result in the autoantibody production that occurs in lupus.
|
By Journal of Clinical Investigation ,
Lupus is a chronic, autoimmune disease that causes inflammation, particularly of the skin, joints, blood, and kidneys. Patients with lupus produce antibodies against their own proteins. Patients also have immune T cells that produce a protein called IL-2, which normally usually protects against infection, at lower than typical levels. In a study appearing in the April 1 print edition of The Journal of Clinical Investigation, George Tsokos and colleagues from the Walter Reed Army Institute of Research explore the mechanisms underlying this decreased IL-2 production.
The researchers find that sera from lupus patients contains antibodies that bind to T cells and activate a complex cellular signaling cascade that ultimately results in decreased IL-2 production. This deficiency in IL-2 could result in the autoantibody production that occurs in lupus.
In an accompanying commentary, Gary Kammer of Arthritis Associates, Inc points out "the contribution by Tsokos and his colleagues�provides a new appreciation and insight into how the microenvironment in lupus can further impinge on a defective T cell to inhibit IL-2 production. From such studies will come the inspiration and novel approaches necessary to develop therapeutic tools to abate disease and improve the quality of life of our patients." 
- TITLE: Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV
View the PDF of this article
AUTHOR CONTACT:
George C. Tsokos
Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Phone: (301) 319-9911; Fax: (301) 319-9133; E-mail: [email protected]
View the PDF of this article at: https://www.the-jci.org/article.php?id=22854
ACCOMPANYING COMMENTARY:
TITLE: Altered regulation of IL-2 production in systemic lupus erythematosus: an evolving paradigm
AUTHOR CONTACT:
Gary M. Kammer
Arthritis Associates Inc., Willoughby, Ohio, USA.
Phone: (440) 953-8700; Fax: (440) 953-8796; E-mail: [email protected]
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
Top of Page
|
|
|
|
